Medtronic

"Medtronic is the global leader in medical technology- alleviating pain, restoring health, and extending life for people with chronic conditions around the world."

Philip Bauch Christopher Gohmert Jon Zahradka

Medtronic

- April 29, 1949 in Minneapolis, Minnesota
- \$15.8 Billion Revenue Year End 4-30-2010
- 7 Business Segments
- Internation Sales in over 120 countries
- Approximately 43,000 employees

Divisions & Sales

	Net :	Sales		
	Flscal	Year		
(dollars in millions)	2010	2009	% Change	
Cardiac Rhythm Disease Management	\$ 5,268	\$ 5,014	5%	
Spinal	3,500	3,400	3	
CardioVascular	2,864	2,437	18	
Neuromodulation	1,560	1,434	9	
Diabetes	1,237	1,114	11	
Surgical Technologies	963	857	12	
Physio-Control	425	343	24	
Total Net Sales	\$15,817	\$14,599	8%	

Net Sales Geographically

Geographic Information

Net sales to external customers by geography are as follows:

(in millions)	United States	Europe	Asia Pacific	Other Foreign	Consolidated
Fiscal Year 2010					
Net sales to external customers	\$9,366	\$4,014	\$1,903	\$534	\$15,817
Long-lived assets*	\$7,573	\$5,431	\$ 253	\$362	\$13,619
Fiscal Year 2009					
Net sales to external customers	\$ 8,987	\$ 3,564	\$ 1,558	\$490	\$14,599
Long-lived assets*	\$ 7,236	\$ 5,660	\$ 185	\$ 286	\$13,367
Fiscal Year 2008					
Net sales to external customers	\$ 8,336	\$ 3,288	\$ 1,437	\$454	\$13,515
Long-lived assets*	\$ 7,456	\$ 4,791	\$ 168	\$ 36	\$12,451

^{*}Excludes other long-term financial instruments and long-term deferred tax assets, net, as applicable.

No single customer represents over 10 percent of the Company's consolidated net sales in fiscal years 2010, 2009 or 2008.

Tools

Buffettology Spreadsheet

<u>GuruFocus</u>

<u>Article</u>

Buffett & Interpretation of Financial Statements

Interpretation of Financial Statements

Current Ratio: 1.9

Goodwill: Increasing

Intangible Assets: \$ 2,559,000,000

Return on Assets: 11.0%

Long term Debt: Paid with NI in 2.24 years

Debt to Shareholders' Equity: .65

Preferred Stock: None

Interpretation of Financial Statements

Retained Earnings: Increasing-\$14.8 Billion

Treasury Stock: Common stock has decreased by 118 million shares since 2003

Capital Expenditures: 18.2% of earnings

Return on Equity: 21.2%

Stock Buybacks: Yes

Borrowings: 27% short-term, 73% long-term


R&D Costs: 36.8% of gross profit, 10.8 % of sales

Borrowings

(in millions)

FIscal Year	Obligation		
2011	\$2,600		
2012	49		
2013	2,221		
2014	569		
2015	1,255		
Thereafter	3,068		
Total long-term debt	9,762		
Less: Current portion of long-term debt	2,600		
Long-term portion of long-term debt	\$7,162		


Graphs




to interest expense due to the change in accounting rules governing convertible debt, and

certain tax adjustments 11.6%

Default




Safety




Default

current year STRETD® 26 Nov 2010	Price	33.84	_	current year TARGD®	Req Return	15.0	%
Dividend Reinvestment Strategy Buy additional shares	EPSttm PE Ratio	2.890	_	Dividend Reinvestment Strategy ■ Buy additional shares □ Invest at the rate below	EPSttm PE Ratio	2.890	
Note: PE Ratio is ave of last 4 yrs	HGrowth Payout	13.17	% %	Note: PE Ratio is ave of last 4 yrs	HGrowth Payout	13.17	% %
vestment Period > years	lividends capital gains	,	∕	Investment Period 5 years	Tax - dividends Tax - capital gains		√ %
Calculate 27.58% per year	Synd	with TARG	1	Calculate \$45.62	Sync	with STRE	Т


Kill It



Default



Kill It Again



Conclusion

Purchase MDT